Naibec Receives Approval for Phase 1 Clinical Trial Plan of Pulmonary Fibrosis Treatment in Australia

[Asia Economy Reporter Lee Jung-yoon] Nivek announced on the 22nd that the Phase 1 clinical trial plan for its peptide-based pulmonary fibrosis treatment (NIPEP-PF, clinical trial code NP-201) in Australia has been approved.

The company stated, "After completing Phase 1 in Australia, depending on the evaluation results of pharmacokinetic characteristics, safety, tolerability, and immunogenicity observed during this clinical process, we plan to proceed to the next phase of patient-targeted clinical trials."